Healthcare

Optiscan Imaging (ASX:OIL) is pushing two of its most important cancer-imaging studies forward faster than planned, giving the small Victorian medical-technology company a rare run of positive clinical momentum as it builds towards the United States market. One study, a breast-cancer surgery trial with …

Radiopharm Theranostics (ASX:RAD) has capped a landmark day for its clinical pipeline by moving to strengthen its balance sheet, raising about $16 million on the back of positive results from not one but two separate cancer trials. The clinical-stage radiopharmaceutical developer, dual-listed on the …

Neurizon Therapeutics (ASX:NUZ) has cleared one of the most important operational hurdles in drug development, confirming that it has finished recruiting patients for the pivotal test of its lead amyotrophic lateral sclerosis (ALS) candidate. The Brisbane-based biotech announced that Regimen I of the prestigious …

Mesoblast (ASX:MSB) has spent the better part of two decades as one of the Australian market's most heavily watched, and most frequently doubted, regenerative-medicine stories. For years it was a company defined by promise rather than product: a deep portfolio of cell therapies, a …

Monash IVF Group (ASX:MVF), one of Australia's best-known assisted-reproduction providers, has become a takeover target at the lowest point in its listed history. A consortium led by private equity firm Genesis Capital and blue-chip investment house Washington H. Soul Pattinson has lobbed an unsolicited …

Micro-X Limited (ASX:MX1) has spent the better part of two decades chasing a deceptively simple idea: that the century-old, hot-filament X-ray tube could be replaced by something smaller, lighter and smarter. The Adelaide-based company builds its imaging products around cold-cathode, carbon-nanotube (CNT) emitter technology, …

• LTR Pharma (ASX:LTP) has secured Strive Pharmacy as its exclusive US 503A pharmacy fulfilment partner for ROXUS across all 50 states.